Abstract:Am 26. April 2007 hat das Antiviral Drugs Advisory Commitee der FDA einstimmig die Empfehlung ausgesprochen, Maraviroc (Celsentri™) für die Therapie von vorbehandelten HIV‐Patienten mit CCR5‐tropen Viren zuzulassen. Die endgültige Entscheidung über die Zulassung wird in den USA im Juli erwartet, in Europa einige Monate später.
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.